Dear Colleagues,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is responsible for the current pandemic and has had a deleterious impact on public health and the global economy. As of Dec 27, 2021, there have been 279 million confirmed cases of COVID-19, including 5.39 million deaths. With no other obvious short-term resolution, mRNA vaccines, recombinant protein vaccines, inactivated vaccines, viral vector-based vaccines, and DNA vaccines seem to be a key strategy to combat COVID-19 around the world. Although, unprecedented in human history, the vaccine-driven relief of the pandemic is expected, the emerging variants are raising concerns about breakthrough infections. These emerging variants will not only keep the host immunity under constant pressure but also render the efficacy of vaccine candidates uncertain. Thus, to overcome this evolving SARS-CoV-2 menace, evolving vaccines and vaccine strategies are required. To that end, this Special Issue will address the current epidemiology and spread of COVID-19 as well as its prevention through effective vaccines.

Dr. Muhammad Atif Zahoor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• advances in vaccines
• vaccine development
• vaccine formulations or technologies
• animal models describing protection against COVID-19